View Item 

Show simple item record

Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double- Blind, Placebo- Controlled Trial
dc.contributor.authorKhanna, Puja P.
dc.contributor.authorKhanna, Dinesh
dc.contributor.authorCutter, Gary
dc.contributor.authorFoster, Jeff
dc.contributor.authorMelnick, Joshua
dc.contributor.authorJaafar, Sara
dc.contributor.authorBiggers, Stephanie
dc.contributor.authorRahman, A. K. M. Fazlur
dc.contributor.authorKuo, Hui‐chien
dc.contributor.authorFeese, Michelle
dc.contributor.authorKivitz, Alan
dc.contributor.authorKing, Charles
dc.contributor.authorShergy, William
dc.contributor.authorKent, Jeff
dc.contributor.authorPeloso, Paul M.
dc.contributor.authorDanila, Maria I.
dc.contributor.authorSaag, Kenneth G.
dc.date.accessioned2021-08-03T18:17:58Z
dc.date.available2022-09-03 14:17:57en
dc.date.available2021-08-03T18:17:58Z
dc.date.issued2021-08
dc.identifier.citationKhanna, Puja P.; Khanna, Dinesh; Cutter, Gary; Foster, Jeff; Melnick, Joshua; Jaafar, Sara; Biggers, Stephanie; Rahman, A. K. M. Fazlur; Kuo, Hui‐chien ; Feese, Michelle; Kivitz, Alan; King, Charles; Shergy, William; Kent, Jeff; Peloso, Paul M.; Danila, Maria I.; Saag, Kenneth G. (2021). "Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double- Blind, Placebo- Controlled Trial." Arthritis & Rheumatology (8): 1523-1532.
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.urihttps://hdl.handle.net/2027.42/168535
dc.publisherWiley Periodicals, Inc.
dc.titleReducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double- Blind, Placebo- Controlled Trial
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168535/1/art41731_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168535/2/art41731.pdf
dc.identifier.doi10.1002/art.41731
dc.identifier.sourceArthritis & Rheumatology
dc.identifier.citedreferenceZeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I, et al. Efficacy and safety of enteric- coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 2011; 20: 1484 - 93.
dc.identifier.citedreferenceLee YH, Song GG. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta- analysis of randomized controlled trials. Lupus 2015; 24: 1520 - 8.
dc.identifier.citedreferenceMeriggioli MN, Ciafaloni E, Al- Hayk KA, Rowin J, Tucker- Lipscomb B, Massey JM, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003; 61: 1438 - 40.
dc.identifier.citedreferenceNeogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol 2015; 67: 2557 - 68.
dc.identifier.citedreferenceHorizon Pharma PLC. KRYSTEXXA ® (pegloticase) [package insert]. 2016.
dc.identifier.citedreferenceKhanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1447 - 61.
dc.identifier.citedreferenceZimmerman R, Radhakrishnan J, Valeri A, Appel G. Advances in the treatment of lupus nephritis [review]. Annu Rev Med 2001; 52: 63 - 78.
dc.identifier.citedreferenceTerkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty- four- hour outcome of the first multicenter, randomized, double- blind, placebo- controlled, parallel- group, dose- comparison colchicine study. Arthritis Rheum 2010; 62: 1060 - 8.
dc.identifier.citedreferenceSchalet BD, Hays RD, Jensen SE, Beaumont JL, Fries JF, Cella D. Validity of PROMIS physical function measures in diverse clinical samples. J Clin Epidemiol 2016; 73: 112 - 8.
dc.identifier.citedreferenceWood R, Fermer S, Ramachandran S, Baumgartner S, Morlock R. Patients with gout treated with conventional urate- lowering therapy: association with disease control, health- related quality of life, and work productivity. J Rheumatol 2016; 43: 1897 - 903.
dc.identifier.citedreferenceSarkin AJ, Levack AE, Shieh MM, Kavanaugh AF, Khanna D, Singh JA, et al. Predictors of doctor- rated and patient- rated gout severity: gout impact scales improve assessment. J Eval Clin Pract 2010; 16: 1244 - 7.
dc.identifier.citedreferenceWallace B, Khanna D, Aquino- Beaton C, Singh JA, Duffy E, Elashoff D, et al. Performance of Gout Impact Scale in a longitudinal observational study of patients with gout. Rheumatology (Oxford) 2016; 55: 982 - 90.
dc.identifier.citedreferenceAllison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action [review]. Immunopharmacology 2000; 47: 85 - 118.
dc.identifier.citedreferenceMehling A, Grabbe S, Voskort M, Schwarz T, Luger TA, Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000; 165: 2374 - 81.
dc.identifier.citedreferenceRothenbacher D, Primatesta P, Ferreira A, Cea- Soriano L, Rodríguez LA. Frequency and risk factors of gout flares in a large population- based cohort of incident gout. Rheumatology (Oxford) 2011; 50: 973 - 81.
dc.identifier.citedreferenceBotson JK, Peterson J. Pretreatment and co- administration with methotrexate improved durability of pegloticase response: a prospective, observational, proof- of- concept, case series. J Clin Rheumatol 2020 doi: 10.1097/RHU.0000000000001639. E- pub ahead of print.
dc.identifier.citedreferenceAlbert JA, Hosey T, LaMoreaux B. Subcutaneous or oral methotrexate exposure and response to pegloticase in uncontrolled gout patients in a community rheumatology practice [abstract]. Arthritis Rheumatol 2019; 71 Suppl 10. URL: https://acrabstracts.org/abstract/subcutaneous-or-oral-methotrexate-exposure-and-response-to-pegloticase-in-uncontrolled-gout-patients-in-a-community-rheumatology-practice/.
dc.identifier.citedreferenceBotson J, Peloso P, Obermeyer K, LaMoreaux B, Weinblatt ME, Peterson J. Pegloticase response improvement by co- treatment with methotrexate: results from the MIRROR open- label clinical trial in patients with uncontrolled gout [abstract]. Ann Rheum Dis 2020; 79: 446.
dc.identifier.citedreferenceRainey H, Baraf HS, Lipsky P. Companion immunosuppression with azathioprine increases the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout [abstract]. Ann Rheum Dis 2020; 79: 438.
dc.identifier.citedreferencePrager D, Rosman M, Bertino JR. Azathioprine and allopurinol [letter]. Ann Intern Med 1974; 80: 427.
dc.identifier.citedreferenceRaman GV, Sharman VL, Lee HA. Azathioprine and allopurinol: a potentially dangerous combination. J Intern Med 1990; 228: 69 - 71.
dc.identifier.citedreferenceJacobs F, Mamzer- Bruneel MF, Skhiri H, Thervet E, Legendre C, Kreis H. Safety of the mycophenolate mofetil- allopurinol combination in kidney transplant recipients with gout [letter]. Transplantation 1997; 64: 1087 - 8.
dc.identifier.citedreferenceMcLeod HL, Kumar A. Metabolism of azathioprine [letter]. Transplantation 1996; 61: 1425.
dc.identifier.citedreferenceDignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, et al. The second European evidence- based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010; 4: 28 - 62.
dc.identifier.citedreferenceTalley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, et al. An evidence- based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011; 106 Suppl 1: S2 - 25.
dc.identifier.citedreferenceBello AE, Perkins EL, Jay R, Efthimiou P. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol 2017; 9: 67 - 79.
dc.identifier.citedreferenceMorgan SL, Baggott JE, Koopman WJ, Krumdieck CL, Alarcón GS. Folate supplementation and methotrexate. Ann Rheum Dis 1993; 52: 315 - 6.
dc.identifier.citedreferenceKeenan RT, O’Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011; 124: 155 - 63.
dc.identifier.citedreferencePerez- Ruiz F, Nolla JM. Influence of leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis. J Clin Rheumatol 2003; 9: 215 - 8.
dc.identifier.citedreferenceLee JJ, Bykerk VP, Dresser GK, Boire G, Haraoui B, Hitchon C, et al. Reduction in serum uric acid may be related to methotrexate efficacy in early rheumatoid arthritis: data from the Canadian Early Arthritis Cohort (CATCH). Clin Med Insights Arthritis Musculoskelet Disord 2016; 9: 37 - 43.
dc.identifier.citedreferenceWang K, Zhang H, Li Y, Wei Q, Li H, Yang Y, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc 2004; 36: 2068 - 70.
dc.identifier.citedreferenceSundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez- Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306: 711 - 20.
dc.identifier.citedreferenceFitzGerald JD, Dalbeth N, Mikuls T, Brignardello- Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 2020; 72: 744 - 60.
dc.identifier.citedreferenceKhanna P, Khanna D, Storgard C, Baumgartner S, Morlock R. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. Postgrad Med 2016; 128: 34 - 40.
dc.identifier.citedreferenceCunha RN, Aguiar R, Farinha F. Impact of pegloticase on patient outcomes in refractory gout: current perspectives [review]. Open Access Rheumatol 2018; 10: 141 - 9.
dc.identifier.citedreferenceSundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol- conjugated uricase) in patients with treatment- failure gout: results of a phase II randomized study. Arthritis Rheum 2008; 58: 2882 - 91.
dc.identifier.citedreferenceLipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther 2014; 16: R60.
dc.identifier.citedreferenceBaraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA. Infusion- related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol 2014; 20: 427 - 32.
dc.identifier.citedreferenceHershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. Induced and pre- existing anti- polyethylene glycol antibody in a trial of every 3- week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther 2014; 16: R63.
dc.identifier.citedreferenceReinders MK, Jansen TL. New advances in the treatment of gout: review of pegloticase [review]. Ther Clin Risk Manag 2010; 6: 543 - 50.
dc.identifier.citedreferenceAlbert JA, Hosey T, LaMoreaux B. Increased efficacy and tolerability of pegloticase in patients with uncontrolled gout co- treated with methotrexate: a retrospective study. Rheumatol Ther 2020; 7: 639 - 48.
dc.identifier.citedreferenceBerhanu AA, Krasnokutsky S, Keenan RT, Pillinger MH. Pegloticase failure and a possible solution: immunosuppression to prevent intolerance and inefficacy in patients with gout. Semin Arthritis Rheum 2017; 46: 754 - 8.
dc.identifier.citedreferenceBessen SY, Bessen MY, Yung CM. Recapture and improved outcome of pegloticase response with methotrexate- a report of two cases and review of the literature. Semin Arthritis Rheum 2019; 49: 56 - 61.
dc.identifier.citedreferenceGuttmann A, Krasnokutsky S, Pillinger MH, Berhanu A. Pegloticase in gout treatment: safety issues, latest evidence and clinical considerations. Ther Adv Drug Saf 2017; 8: 379 - 88.
dc.identifier.citedreferenceSollinger HW, on behalf of the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225 - 32.
dc.identifier.citedreferenceSrinivas TR, Kaplan B, Meier- Kriesche HU. Mycophenolate mofetil in solid- organ transplantation. Expert Opin Pharmacother 2003; 4: 2325 - 45.
dc.identifier.citedreferenceGinzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219 - 28.
dc.identifier.citedreferenceKamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta- analysis. Medicine (Baltimore) 2010; 89: 227 - 35.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art41731_am.pdf
Size:
386.3KB
Format:
PDF
View/Open
Name:
art41731.pdf
Size:
609.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.